JP2017522043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522043A5 JP2017522043A5 JP2017510285A JP2017510285A JP2017522043A5 JP 2017522043 A5 JP2017522043 A5 JP 2017522043A5 JP 2017510285 A JP2017510285 A JP 2017510285A JP 2017510285 A JP2017510285 A JP 2017510285A JP 2017522043 A5 JP2017522043 A5 JP 2017522043A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000338 in vitro Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 51
- 239000012634 fragment Substances 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000000209 Isaacs syndrome Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims 1
- 206010072359 Neuromyotonia Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000004403 episodic ataxia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461986742P | 2014-04-30 | 2014-04-30 | |
| US61/986,742 | 2014-04-30 | ||
| PCT/KR2015/004424 WO2015167293A1 (en) | 2014-04-30 | 2015-04-30 | Antibody binding to fcrn for treating autoimmune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522043A JP2017522043A (ja) | 2017-08-10 |
| JP2017522043A5 true JP2017522043A5 (2) | 2018-03-22 |
| JP6449441B2 JP6449441B2 (ja) | 2019-01-09 |
Family
ID=54358928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510285A Active JP6449441B2 (ja) | 2014-04-30 | 2015-04-30 | ＦｃＲｎ特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US10544226B2 (2) |
| EP (2) | EP3137504B1 (2) |
| JP (1) | JP6449441B2 (2) |
| KR (2) | KR101954906B1 (2) |
| CN (2) | CN106459215B (2) |
| AU (2) | AU2015253915B2 (2) |
| CA (2) | CA2945086C (2) |
| DK (1) | DK3137504T5 (2) |
| EA (1) | EA038470B1 (2) |
| ES (1) | ES2952583T3 (2) |
| FI (1) | FI3137504T3 (2) |
| HU (1) | HUE062403T2 (2) |
| IL (2) | IL248159B (2) |
| MX (2) | MX382284B (2) |
| NZ (2) | NZ726089A (2) |
| PL (1) | PL3137504T3 (2) |
| PT (1) | PT3137504T (2) |
| RS (1) | RS64542B1 (2) |
| SA (1) | SA516380194B1 (2) |
| SG (1) | SG11201608208VA (2) |
| WO (1) | WO2015167293A1 (2) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106957365B (zh) | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| ES2864211T3 (es) * | 2016-04-25 | 2021-10-13 | Syntimmune Inc | Anticuerpos anti-FcRn humanizados con maduración de la afinidad |
| CA3032415A1 (en) * | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| SG11201911832PA (en) * | 2017-06-15 | 2020-01-30 | UCB Biopharma SRL | Method for the treatment of immune thrombocytopenia |
| KR102904658B1 (ko) | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| KR102921210B1 (ko) | 2018-07-20 | 2026-01-30 | 모멘타 파머슈티컬스 인코포레이티드 | Fcrn 항체 조성물 |
| MA53903A (fr) | 2018-10-16 | 2021-08-25 | UCB Biopharma SRL | Méthode de traitement de la myasthénie grave |
| US20220002402A1 (en) * | 2018-11-06 | 2022-01-06 | Immunovant Sciences Gmbh | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies |
| GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| US20230049011A1 (en) | 2019-11-19 | 2023-02-16 | Immunovant Sciences Gmbh | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies |
| CN114341184B (zh) * | 2020-02-10 | 2023-04-04 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
| KR20220001482A (ko) * | 2020-06-29 | 2022-01-05 | 한올바이오파마주식회사 | 항-FcRn 항체에 대한 제형 |
| CN116490208A (zh) * | 2020-08-06 | 2023-07-25 | 史坦利科西斯治疗有限责任公司 | Il-8抗体及其使用方法 |
| CN113484526B (zh) * | 2021-08-11 | 2024-08-23 | 上海迈晋生物医药科技有限公司 | 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法 |
| US20250136699A1 (en) * | 2021-08-13 | 2025-05-01 | Jiangsu Biojetay Biotechnology Co., Ltd. | Antibodies specifically recognizing fcrn and uses thereof |
| US20250026814A1 (en) * | 2021-11-16 | 2025-01-23 | The University Of Chicago | Polypeptides for detection and treatment of coronavirus infection |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| AU2023281650A1 (en) * | 2022-05-30 | 2024-10-17 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| TW202409085A (zh) | 2022-05-30 | 2024-03-01 | 南韓商韓兀生物製藥股份有限公司 | 具有改善之安定性的抗ＦｃＲｎ抗體或其抗原結合片段 |
| MA71603A (fr) * | 2022-07-27 | 2025-05-30 | Ablynx Nv | Polypeptides se liant à un épitope spécifique du récepteur fc néonatal |
| WO2024052358A1 (en) | 2022-09-06 | 2024-03-14 | Immunovant Sciences Gmbh | Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies |
| US20260078188A1 (en) | 2022-09-06 | 2026-03-19 | Immunovant Sciences Gmbh | Methods of treating graves’ disease using anti-fcrn antibodies |
| EP4676963A1 (en) | 2023-03-08 | 2026-01-14 | Immunovant Sciences GmbH | High concentration protein formulations with polysorbate excipients and methods of making the same |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| CN121843716A (zh) | 2023-07-16 | 2026-04-10 | 阿根思有限公司 | 用于治疗慢性炎性脱髓鞘性多发性神经病的方法 |
| WO2025093717A1 (en) * | 2023-10-31 | 2025-05-08 | Immunovant Sciences Gmbh | Methods of improving anti-fcrn therapies |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| CN119490588B (zh) * | 2024-10-17 | 2026-03-06 | 广州康盛生物科技股份有限公司 | 一种抗人FcRn的VHH抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| JP2007501847A (ja) | 2003-08-08 | 2007-02-01 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体 |
| US7662928B2 (en) * | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CA2606378A1 (en) * | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
| JP2009524664A (ja) | 2006-01-25 | 2009-07-02 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体 |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| BRPI0910622A2 (pt) * | 2008-04-25 | 2020-03-10 | Dyax Corp. | ANTICORPOS CONTRA FcRn E USOS DOS MESMOS |
| KR102014554B1 (ko) * | 2011-06-02 | 2019-08-26 | 다이액스 코포레이션 | Fc 수용체 결합 단백질 |
| KR20130071961A (ko) * | 2011-12-21 | 2013-07-01 | 한올바이오파마주식회사 | ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| KR20210094669A (ko) | 2013-04-29 | 2021-07-29 | 에프. 호프만-라 로슈 아게 | 인간 fcrn-결합 변형된 항체 및 사용 방법 |
| KR101815265B1 (ko) * | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
-
2015
- 2015-04-30 FI FIEP15785500.8T patent/FI3137504T3/fi active
- 2015-04-30 HU HUE15785500A patent/HUE062403T2/hu unknown
- 2015-04-30 DK DK15785500.8T patent/DK3137504T5/da active
- 2015-04-30 ES ES15785500T patent/ES2952583T3/es active Active
- 2015-04-30 SG SG11201608208VA patent/SG11201608208VA/en unknown
- 2015-04-30 WO PCT/KR2015/004424 patent/WO2015167293A1/en not_active Ceased
- 2015-04-30 CN CN201580029793.2A patent/CN106459215B/zh active Active
- 2015-04-30 CA CA2945086A patent/CA2945086C/en active Active
- 2015-04-30 RS RS20230636A patent/RS64542B1/sr unknown
- 2015-04-30 PL PL15785500.8T patent/PL3137504T3/pl unknown
- 2015-04-30 CA CA3095295A patent/CA3095295C/en active Active
- 2015-04-30 NZ NZ726089A patent/NZ726089A/en unknown
- 2015-04-30 NZ NZ737666A patent/NZ737666A/en unknown
- 2015-04-30 JP JP2017510285A patent/JP6449441B2/ja active Active
- 2015-04-30 MX MX2016014210A patent/MX382284B/es unknown
- 2015-04-30 AU AU2015253915A patent/AU2015253915B2/en active Active
- 2015-04-30 EP EP15785500.8A patent/EP3137504B1/en active Active
- 2015-04-30 KR KR1020187023165A patent/KR101954906B1/ko active Active
- 2015-04-30 CN CN202010031615.6A patent/CN111138540B/zh active Active
- 2015-04-30 EA EA201692192A patent/EA038470B1/ru unknown
- 2015-04-30 US US15/301,948 patent/US10544226B2/en active Active
- 2015-04-30 PT PT157855008T patent/PT3137504T/pt unknown
- 2015-04-30 EP EP23172456.8A patent/EP4241852A3/en active Pending
- 2015-04-30 KR KR1020167032395A patent/KR101889466B1/ko active Active
-
2016
- 2016-09-29 IL IL248159A patent/IL248159B/en active IP Right Grant
- 2016-10-28 MX MX2021005193A patent/MX2021005193A/es unknown
- 2016-10-30 SA SA516380194A patent/SA516380194B1/ar unknown
-
2018
- 2018-05-22 AU AU2018203582A patent/AU2018203582B2/en active Active
-
2019
- 2019-01-15 US US16/248,083 patent/US20190135917A1/en not_active Abandoned
- 2019-12-11 US US16/710,318 patent/US11613578B2/en active Active
-
2021
- 2021-02-03 IL IL280613A patent/IL280613B/en unknown
-
2023
- 2023-02-21 US US18/171,967 patent/US20230235063A1/en active Pending
- 2023-11-17 US US18/512,775 patent/US20240092913A1/en not_active Abandoned
-
2024
- 2024-07-03 US US18/763,278 patent/US20250026835A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522043A5 (2) | ||
| JP7453206B2 (ja) | 改良された血清アルブミン結合剤 | |
| JP2014526898A5 (2) | ||
| JP2013538057A5 (2) | ||
| FI3137504T3 (fi) | Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten | |
| JP2020525032A5 (2) | ||
| JP2018512138A5 (2) | ||
| JP2017522903A5 (2) | ||
| JP2018502561A5 (2) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2017113028A5 (2) | ||
| JP2018537421A5 (2) | ||
| JP2016507555A5 (2) | ||
| JP2016511277A5 (2) | ||
| JP2019536806A5 (2) | ||
| JP2014524733A5 (2) | ||
| JP2011514150A5 (2) | ||
| JP2018502060A5 (2) | ||
| JP2018535650A5 (2) | ||
| JP2015517470A5 (2) | ||
| JP2020502996A5 (2) | ||
| JP2017531427A5 (2) | ||
| JP2012501670A5 (2) | ||
| JP2014500009A5 (2) | ||
| JP2018527919A5 (2) |